Crescent Biopharma Inc (NASDAQ: CBIO) is -46.34% lower on its value in year-to-date trading and has touched a low of $11.06 and a high of $63.00 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The CBIO stock was last observed hovering at around $15.55 in the last trading session, with the day’s gains setting it 0.34%.
Currently trading at $15.89, the stock is -2.64% and -24.52% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.17 million and changing 2.22% at the moment leaves the stock -35.03% off its SMA200. CBIO registered -36.18% loss for a year compared to 6-month loss of -36.11%. The firm has a 50-day simple moving average (SMA 50) of $21.0518 and a 200-day simple moving average (SMA200) of $24.45795.
The stock witnessed a -23.97% gain in the last 1 month and extending the period to 3 months gives it a -24.23%, and is -5.98% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 9.82% over the week and 17.37% over the month.
Crescent Biopharma Inc (CBIO) has around 26 employees, a market worth around $10.25M and $0.00M in sales. Distance from 52-week low is 43.67% and -74.78% from its 52-week high. The company has generated returns on investments over the last 12 months (-873.60%).
The EPS is expected to grow by 92.98% this year
40.0 institutions hold shares in Crescent Biopharma Inc (CBIO), with institutional investors hold 12.10% of the company’s shares. The shares outstanding are 0.65M, and float is at 0.58M. Institutions hold 12.09% of the Float.
Crescent Biopharma Inc (CBIO) Insider Activity
The most recent transaction is an insider sale by Invus Public Equities, L.P., the company’s 10% Owner. SEC filings show that Invus Public Equities, L.P. sold 260,873 shares of the company’s common stock on Aug 08 ’24 at a price of $0.19 per share for a total of $50009.0. Following the sale, the insider now owns 6.32 million shares.
Crescent Biopharma Inc disclosed in a document filed with the SEC on Aug 07 ’24 that Invus Public Equities, L.P. (10% Owner) sold a total of 61,488 shares of the company’s common stock. The trade occurred on Aug 07 ’24 and was made at $0.18 per share for $11197.0. Following the transaction, the insider now directly holds 6.58 million shares of the CBIO stock.
Still, SEC filings show that on Aug 05 ’24, Invus Public Equities, L.P. (10% Owner) disposed off 164,523 shares at an average price of $0.19 for $30996.0. The insider now directly holds 6,695,658 shares of Crescent Biopharma Inc (CBIO).
